V. A. Miller, V. Hirsh, J. Cadranel, et al., “Phase IIb/III Double-Blind Randomized Trial of BIBW 2992, an Irreversible Inhibitor of EGFR/HER1 and HER2 + Best Supportive Care (BSC) versus Placebo + BSC in Patients with NSCLC Failing 1-2 Lines of Chemotherapy and Erlotinib or Gefitinib (LUX-Lung 1),” European Society of Medical Oncology (ESMO) Congress, Milan, 8-12 October 2010, Abstract LBA1.

has been cited by the following article: